This invention relates to a method of treating multiple sclerosis in a mammalian patient, preferably a human, in need of such treatment, comprising administering to said human an S1P receptor modulator or agonist according to a dosing regimen that is determined with reference to the patient’s blood lymphocyte count.本發明係關於治療需要該治療之哺乳動物患者、較佳人類之多發性硬化症之方法,其包含根據參考該患者之血液淋巴細胞計數所測定之給藥療法向該人類投與S1P受體調節劑或促效劑。